BACKGROUND: The use of nuclear transfer (NT) has been proposed as a novel reproductive treatment to overcome the transmission of maternally-inherited mitochondrial DNA (mtDNA) mutations. Pathogenic mutations in mtDNA can cause a wide-spectrum of lifelimiting disorders, collectively known as mtDNA disease, for which there are currently few effective treatments and no known cures. The many unique features of mtDNA make genetic counselling challenging for women harbouring pathogenic mtDNA mutations but reproductive options that involve medical intervention are available that will minimize the risk of mtDNA disease in their offspring. This includes PGD, which is currently offered as a clinical treatment but will not be suitable for all. The potential for NT to reduce transmission of mtDNA mutations has been demonstrated in both animal and human models, and has recently been clinically applied not only to prevent mtDNA disease but also for some infertility cases. In this review, we will interrogate the different NT techniques, including a discussion on † These authors contributed equally to this work.
Introduction
Mitochondria are essential organelles present in eukaryotic cells mostly recognized for their role in generating cellular energy through oxidative phosphorylation (OXPHOS). Mitochondrial disease is the collective term for a discrete group of neurometabolic disorders that conventionally lead to defective OXPHOS, usually affecting organs heavily dependent on aerobic metabolism (McFarland et al., 2010) . They are frequently delineated by multi-system involvement, giving rise to a capacious spectrum of clinical symptoms that are often relentlessly progressive, associated with formidable disease burden and premature morbidity and mortality (Gorman et al., 2016) . Mitochondrial disorders manifest with important genotypic and phenotypic heterogeneity. Well recognized clinical syndromes related to mitochondrial disease include Kearns-Sayre Syndrome (KSS) (Kearns and Sayre, 1958) , Leigh syndrome (Ciafaloni et al., 1993 ), Leber's Hereditary Optic Neuropathy (LHON) (Wallace et al., 1988) , myoclonic epilepsy, lactic acidosis, stroke-like episodes (MELAS) (Pavlakis et al., 1984) , myoclonic epilepsy, with ragged red fibres (MERRF) (Fukuhara et al., 1980) , and neurogenic weakness with ataxia and retinitis pigmentosa (NARP) (Holt et al., 1988) . However, in the majority of cases, clinical manifestations are often varied, with overlapping disease spectrums opposed to distinct clinical entities.
While the advent of next generation sequencing is in the process of reforming our diagnostic approach, it is somewhat fortuitous that diagnostic yield is still reliant on the fastidious clinical and biochemical characterization of patients. Mitochondrial disease is genetically heterogeneous and can be caused by mutations in both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Point prevalence estimates of all forms of childhood-onset and adult-onset mitochondrial disease range from 5 to 15 per 100 000 in childhood (Gorman et al., 2016) to 12.5 per 100 000 in clinically affected adults, with an estimated point prevalence of 23 per 100 000 of all pathogenic mutations (Gorman et al., 2015b) .
Whilst there have been recent rapid developments in the field of mitochondrial medicine and pivotal steps made in our understanding of the genetic basis of mitochondrial diseases, including emerging therapies, unfortunately there remain few proven treatments and no known cures (Nightingale et al., 2016) . And yet it has been the improvement in our understanding of the genetic complexities of these disorders that is revolutionizing our approach to genetic counselling for reproductive purposes in families harbouring both nuclear and mtDNA pathogenic mutations. Women of reproductive age harbouring nDNA or mtDNA-related mitochondrial disease pathogenic mutations have several options available to them. Current options available include opting not to have children, adoption, oocyte donation, PGD and prenatal diagnosis. However, some of these strategies will not give women harbouring mtDNA pathogenic mutations the chance of having a genetically related child, due to the limited reproductive options available to them. New technologies, such as the application of nuclear transfer, have therefore been proposed and investigated to prevent the transmission of mitochondrial disease.
Methods
We investigated the scientific literature by searching PubMed database until Jan 2017. Relevant documents from the Human Fertilisation and Embryology Authority (HFEA) as well as reports from both the scientific and popular media are also implemented. The above searches were based on the following key words: 'mitochondria', 'mitochondrial DNA (mtDNA)'; 'mitochondrial DNA disease', 'fertility'; 'preimplantation genetic diagnosis', 'nuclear transfer', 'mitochondrial replacement' and 'mitochondrial donation'.
Mitochondrial DNA
Mitochondria are unique in that they possess their own genome (mtDNA) which, in humans, is a small (~16.6 kb) circular molecule containing only 37 genes. Thirteen of these genes encode protein subunits of the OXPHOS system, with the other 24 genes required for mitochondrial protein synthesis. The remaining~1145 proteins necessary for mitochondrial function (Calvo et al., 2016) are encoded by the nuclear DNA and as such, mitochondrial function is under dual genetic control of both the mitochondrial and nuclear genome. There are many unique features of mtDNA that are crucial to the understanding of mtDNA disease, including the multicopy nature of the mtDNA genome, with different cell types containing different numbers of mtDNA molecules. This is exemplified by human gametes, with mtDNA copy numbers ranging from~100 mtDNA copies in sperm to >100 000-600 000 mtDNA copies in mature oocytes. These mtDNA genomes will either have identical mtDNA genotypes (a situation termed homoplasmy) or will be a mixture of different genotypes (a situation termed heteroplasmy), which becomes significant when a pathogenic mtDNA mutation is present (Fig. 1A) . Importantly, in heteroplasmic individuals, it is the proportion of mutated to wild-type mtDNA that determines expression of disease, with higher mutation loads often associated with more severe symptoms. This is known as the threshold effect, whereby the level of mtDNA mutation must exceed a critical threshold before clinical symptoms occur (Fig. 1C ). This is generally thought to be 60-80% mutation load, but can vary depending on the particular mtDNA mutation (Shoffner et al., 1990; White et al., 1999; de Laat et al., 2012) and for some diseases, this threshold remains unknown.
Another distinct feature of mtDNA is that it exhibits strict maternal inheritance (Pyle et al., 2015) (Fig. 2A) , most likely due to targeted destruction of paternal mtDNA within the oocyte after fertilization (Song et al., 2016; Zhou et al., 2016) (Fig. 2B ). This has obvious implications for women carrying a pathogenic mtDNA mutation, as there is a significant risk that this mutation will be transmitted to the offspring. The risk is very difficult to predict, however, because of another unusual characteristic of mtDNA known as the mitochondrial genetic bottleneck (Fig. 1B) . This is thought to involve a sharp decline in the mtDNA copy number during development of the female germline (Cree et al., 2008; Wai et al., 2008; Neupane et al., 2015) , with transmission of a limited number of mtDNA molecules within primordial germ cells (PGCs) leading to rapid shifts in heteroplasmy both within and between generations ( Fig. 1B and C) . This can make genetic counselling for women who carry pathogenic mtDNA mutations very challenging, especially as asymptomatic carriers with low mutation loads can produce oocytes with very high mutation loads (Fig. 1C) . Indeed, genetic counselling for women harbouring pathogenic mtDNA mutations is further complicated by conspicuously different mtDNA heteroplasmy levels in their offspring, the variability in penetrance of disease-causing mutations and the disparity in critical mutant mtDNA level thresholds that result in organ dysfunction and clinical disease expression.
Preimplantation genetic diagnosis for mitochondrial DNA diseases
Current conventional approaches for preventing mtDNA disease transmission involve prenatal diagnosis and PGD. Prenatal diagnosis is a technique that samples cells at different stages of early pregnancy and can be used to reduce the risk of severe mtDNA disease, with the option of termination when the mutation load is high (Nesbitt et al., 2014) . The main difficulty with prenatal diagnosis is that the mtDNA mutation load can vary between tissues and can also depend on the stage of foetal development when sampling was performed . This, together with the peculiarities of mtDNA inheritance, make it very arduous to determine a safe threshold below which mtDNA disease is unlikely to manifest in the future child.
PGD is an IVF-based technique, developed over two decades ago (Handyside et al., 1990) , that has more recently been applied to reduce or eliminate the risk of mtDNA disease. This involves genetic testing of one or more cells removed from an early embryo and enables the selection of mutation-free or low mutation load embryos for transfer to the uterus (Hellebrekers et al., 2012; Smeets et al., 2015) . For this to be reliable, it is fundamental that the mtDNA mutation load determined in the biopsy is representative of the entire embryo, which requires uniform segregation of the mtDNA mutation during preimplantation embryo development. Studies in heteroplasmic mouse models have confirmed minimal variation among blastomeres (2% on average) (Dean et al., 2003) , with occasional outliers reported . In contrast, studies in non-human primate embryos have revealed remarkable variation in the level of heteroplasmic mtDNA between blastomeres (Lee et al., 2012) , which could be partly due to the experimental procedures used to create the heteroplasmic embryos (Steffann et al., 2014) . Moreover, limited studies in human embryos have revealed low levels of heteroplasmic variation between the blastomeres of cleavage-stage embryos Treff et al., 2012; Sallevelt et al., 2013) , with some exceptions (Vandewoestyne et al., 2012; Sallevelt et al., 2013) . A strong correlation in the heteroplasmy level has also been reported between trophectoderm cell biopsies and the remaining blastocyst in both mouse models and human embryos carrying mtDNA mutations (Treff et al., 2012; Heindryckx et al., 2014) .
The first successful case of PGD to reduce the risk of mtDNA disease was reported by Steffann et al. (2006) , who performed blastomere biopsy in a NARP patient (m.8993T>G), eventually leading to the birth of a healthy baby (Steffann et al., 2006) . After that, a number of children have since been born using PGD to reduce the transmission of specific mtDNA mutations. These have mainly involved blastomere biopsy (Steffann et al., 2006 (Steffann et al., , 2014 Thorburn et al., 2009; Monnot et al., 2011; Sallevelt et al., 2013 Sallevelt et al., , 2017 and trophectoderm biopsy at the blastocyst stage (Treff et al., 2012; Heindryckx et al., 2014) . The latter has the advantage of providing more cells for testing, which should improve accuracy without jeopardizing embryonic development when compared to cleavage stage biopsy (Cimadomo et al., 2016) . In the first case of blastocyst biopsy, an embryo containing 12% mtDNA mutation load was transferred resulting in a baby with mutation loads ranging from undetectable to 15% in various tissues (Treff et al., 2012; Mitalipov et al., 2014) . The outcome was later subject to some disagreement, however, as reanalysis in another laboratory of the child at 6 weeks and 18 months of age revealed mtDNA mutation loads of 42% and 52% respectively . The child suffered from complex neurologic and multisystem problems, which were neither specific nor typical for m.3243A>G-related mitochondrial disease; still they could have related to problems in the perinatal course such as preeclampsia and intrauterine growth restriction, which are both associated with this mtDNA mutation.
Overall, these PGD results show that the mtDNA mutation load determined in the embryo correspond to the mutation load at birth and confirm that PGD is a feasible option to reduce the risk of mtDNA disease in some women who carry a pathogenic mtDNA mutation. For it to be successful, however, the woman must produce embryos with mutation levels below the critical threshold for disease expression. It can be difficult to provide advice on the percentage threshold below which clinical symptoms are unlikely to occur in later adult life. This safety level coincides with the type of mutation and the associated clinical features. Some mtDNA mutations show a full range of mutation loads, such as the m.3243A>G mutation, while others show a more skewed distribution, such as the m.8993T>G mutation (Blok et al., 1997; Steffann et al., 2015) . Additional information will become available with more PGD cases and follow-up of the children born following PGD for mtDNA disease. The couple's wishes must also be taken into account, as in some cases, the couple may opt to have an embryo transferred containing a mutation load higher than a certain threshold, as this would still be a risk reduction compared to reproducing naturally (Bredenoord et al., 2008) . Based on a meta-analysis of available pedigree data generated so far, a mutation load of 18% was calculated to be associated with a 95% or higher chance of being unaffected, irrespective of the kind of point mutation (Hellebrekers et al., 2012) . This percentage threshold has often been used in reported PGD studies, and in most patients, embryos are identified with a mutation load lower than 18% following multiple ICSI cycles. The exact threshold is still arbitrary and it is speculated that other, yet-to-be-determined factors (including nuclear factors) will play a pivotal role. Moreover, not all embryos containing a mutation load below the threshold will give rise to a successful pregnancy. As a result, PGD will not be a suitable reproductive option for all women who carry a pathogenic mtDNA mutation, including women with homoplasmic mtDNA mutations or those who produce only oocytes with high mutation loads. This highlights the In humans, the copy number of mtDNA molecules within preimplantation embryos undergoes continuous reduction to a lowest level when primordial germ cells (PGCs) (10-200 copies) are formed. Hereafter, the mtDNA copy number displays an increase of~100-fold to~100 000-fold as the oocytes mature to metaphase II (MII) stage (replicative segregation). (C) During replicative segregation, wild-type and mutant mtDNA could exhibit uneven distribution by random segregation, leading to various levels of mtDNA mutation, which can be transmitted from the mother to the next-generation, resulting in huge tissue (oocytes/embryos) variation of mutated mtDNA in affected cells. The ratio of mutant to wild-type mtDNA will determine the severity of the condition, and above a certain threshold, clinical manifestation of the mtDNA disease will occur. need for alternative techniques to reduce the risk of mtDNA disease transmission, such as nuclear transfer.
The use of nuclear transfer technologies in animal and human models
The development of germline nuclear transfer (NT) techniques, also known as mitochondrial donation according to UK law, provide an alternative reproductive option that may allow women with pathogenic mtDNA mutations to have a genetically related child whilst reducing the risk of mtDNA disease Richardson et al., 2015; Wolf et al., 2015) . This novel IVF treatment involves removal of the nuclear genome from an oocyte or zygote that carries an mtDNA mutation, followed by transfer to an enucleated donor oocyte or zygote with wild-type mtDNA. The reconstituted oocyte or zygote will contain mostly mtDNA from the recipient donor oocyte or zygote and as such, reduce the risk of severe mtDNA disease in the offspring (Richardson et al., 2015) (Fig. 3A) . The nuclear genome can be transferred from unfertilized oocytes using techniques such as maternal spindle transfer (MST), polar body transfer (PBT) and germinal vesicle transfer (GVT), or can be transferred from fertilized oocytes (zygotes) using a technique known as pronuclear transfer (PNT). Notably, PNT and MST are the most well studied to date, with more scientific data available to confirm the potential of these NT techniques to prevent transmission of mtDNA disease. These data mainly include the developmental competence of reconstructed embryos, which needs to be considered in combination with embryo quality, and the level of karyoplast-derived mtDNA (mtDNA carryover) transferred with the nuclear genome. It is vital that this level is minimal to reduce the risk of mtDNA disease in the offspring (Samuels et al., 2013) .
The methodology required for nuclear transfer between oocytes or zygotes was initially developed using animal models. Some of the very early studies were published before the identification of itance, meaning that mutant mtDNA carried by a man cannot be transmitted to his children. In cases where the woman's oocytes contain a homoplasmic mtDNA mutation, all children will be carriers and may all be affected (presuming complete penetrance). If the woman's oocytes contain a heteroplasmic mtDNA mutation, all children may be carriers with clinical manifestations dependent on mutation penetrance, heteroplasmy levels and other factors (as yet to be fully elucidated). (B) Schematic diagram showing the mechanism of maternal inheritance of mtDNA which is due to destruction of paternal mtDNA through either ubiquitination or the lysozomal pathway. pathogenic mtDNA mutations (Holt et al., 1988; Wallace et al., 1988) and so the possibility of using NT to prevent transmission of mtDNA disease had not been considered (Rubenstein et al., 1995) . Such studies were important, however, as they experimentally demonstrated the feasibility of different transfer techniques, revealing the potential for onward development of reconstituted oocytes/ zygotes and the birth of healthy offspring. Since then, nuclear transfer studies have been published in a number of different animal models and have confirmed the potential of these techniques to prevent mtDNA disease (Tachibana et al., 2009; Wang et al., 2014) . More recent studies have performed NT using human oocytes and, in some instances, found that the methodology used in animal oocytes could not be directly applied to human oocytes. This highlights the importance of performing such experiments in humans, as the outcomes are critical for evaluating both the safety and efficacy of NT before it is offered as a clinical treatment. The most detailed preclinical study in human oocytes to date focused on PNT to reduce the risk of mtDNA disease transmission (Hyslop et al., 2016) but similar data is also available, although to a lesser extent, for MST and PBT (Tachibana et al., 2013; Kang et al., 2016; Ma et al., 2017) . Importantly, there are currently no scientific data that favour the use of PNT over MST, or vice versa, to reduce the risk of mitochondrial disease. Consequently, the development of both PNT and MST in animal and human studies will be discussed in detail, followed by a brief discussion of PBT and GVT.
Pronuclear transfer
After normal fertilization, two pronuclei (PNs) with defined membranes become visible and migrate to the centre of the zygote, each containing a haploid set of chromosomes. The method of PNT involves removing these and transferring them to a recipient zygote that has had its own PN removed (Fig. 3A ). An efficient method to perform this transfer between mouse zygotes was developed over , first/second polar body transfer (PB1T/PB2T) and germinal vesicle transfer (GVT): briefly, the karyoplast was isolated from the patient oocyte/zygote, and then transferred into the enucleated recipient oocyte/zygote. (B) During NT procedure, the perinuclear mitochondria from nucleus donor could inevitably be carried over into the recipient cytoplast, which can give rise to relatively low level of karyoplast-derived mtDNA heteroplasmy in the reconstructed embryos.
thirty years ago by McGrath and Solter (1983) , and has since formed the basis of all recent NT techniques. Briefly, the method involved removal of the PNs from a donor zygote in the presence of cytoskeletal inhibitors (cytochalasin B and colcemid or nocodazole), which allowed them to be removed within a membrane-bound karyoplast containing a small amount of cytoplasm, and resulted in improved zygote survival after the procedure. This was followed by transfer of the karyoplast to an enucleated zygote with a cell-fusing agent known as HVJ-E (haemagluttinating virus of Japan envelope) (Fig. 3A) . After culture, 96% of reconstituted zygotes developed to the morulae or blastocyst stage and resulted in live offspring following transfer to pseudopregnant females (live birth rate: 16%) (McGrath and Solter, 1983) . Using a similar technique, Meirelles and Smith (1997) performed PNT between zygotes from two strains of mice with different mtDNA genotypes, allowing them to study mtDNA segregation during preimplantation development. Analysis of the reconstituted zygotes revealed that the mean level of karyoplast-derived mtDNA was 19% (range: 16-23%), whilst the level within tissues of the resultant offspring varied from 0% to 69% (Meirelles and Smith, 1997) (Table I) . It is important to note, however, that the overall aim of the study was to produce heteroplasmic mice and as such, efforts were not made to minimize karyoplast-derived mtDNA. This is reflected in the mtDNA carryover levels reported, which are considerably higher when compared to a more recent publication that determined an average mtDNA carryover of 0.29% following PNT in mice (Table I) . A more relevant study published by Sato et al. (2005) described the use of PNT using a mouse model of mitochondrial disease (mito-mouse) with a large-scale mtDNA deletion (ΔmtDNA) responsible for respiration defects within the mice. The findings confirmed that PNT could be used to reduce transmission of mutated mtDNA but also revealed that resultant offspring could survive longer than offspring from unmanipulated control zygotes, further supporting the use of PNT for prevention of mtDNA disease (Sato et al., 2005) (Table I) .
The first study to perform PNT using human zygotes was a proofof-concept study published by Craven et al. (2010) . In this study, PNs were exchanged between abnormally fertilized (1PN or 3PN) human zygotes. This successfully reduced levels of mtDNA carryover to an average of <2%, with the majority of reconstituted zygotes containing undetectable levels of karyoplast-derived mtDNA. The rate of blastocyst formation after PNT was reduced in comparison to unmanipulated controls (8.3% vs 16.6%, respectively) ( Table I ), but could be explained by the absence of a paternal/maternal genome or an incorrect number of centrosomes within the reconstituted zygotes since abnormally fertilized zygotes were used. Moreover, given that abnormally fertilized zygotes frequently arrest during preimplantation embryonic development, it is unlikely that the blastocyst rate would be equivalent to normal zygotes even without manipulation (Craven et al., 2010) (Table I ). More recently, Hyslop et al. (2016) reported the first preclinical study on PNT using normally fertilized (2PN) human zygotes. The study revealed that the PNT protocol previously developed for abnormally fertilized human zygotes was not well tolerated in normal zygotes and, in order to further improve PNT efficiency, the protocol needed to be refined. The major modification involved a change in the timing of PNT, with PN transfer shortly after meiosis II completion (~8 h post-ICSI, early PNT) rather than before the first mitosis (~16 h post-ICSI, late PNT), which improved survival of the resulting zygotes (92% for early PNT vs 59% for late PNT) ( Table I) . This led to a significantly improved blastocyst rate of 62% (in the autologous PNT group) (Table I ) and promoted development of good quality blastocysts. The mtDNA carryover was < 2% in the majority of PNT blastocysts, whilst analysis of aneuploidy and global gene expression revealed no significant differences between early PNT blastocysts and unmanipulated controls. However, Hyslop et al. (2016) also observed in one out of five human embryonic stem cell (hESC) lines derived from early PNT blastocysts that the level of karyoplast-derived mtDNA progressively increased during culture despite an initial low level at the blastocyst stage (Hyslop et al., 2016) (Table I) (Fig. 3B) . This led the authors to conclude that PNT has the potential to greatly reduce the risk of mtDNA disease but may not completely guarantee prevention and, as such, should be considered in conjunction with prenatal screening.
Maternal spindle transfer
The maternal spindle, or metaphase II (MII) spindle-chromosome complex, is formed within oocytes during the second meiotic division. The method of MST involves removing the spindle, and transferring it to an enucleated MII oocyte that has had its own spindle removed, followed by fertilization of the reconstituted oocyte (Fig. 3A) . This is possible because the MII spindle is a microtubular structure with birefringent properties, which allows it to be visualized using polarized microscopy rather than invasive fluorescent staining. The first efficient method for MST was reported in non-human primates (Macaca mulatta) by Tachibana et al. (2009) . In this experiment, the spindle-chromosome complex of donor MII oocytes was removed as a karyoplast and transferred to an enucleated MII recipient oocyte with HVJ-E (Fig. 3A) . The resulting oocytes had comparable fertilization (by ICSI) and blastocyst rates (95% and 61%, respectively) to those of unmanipulated control oocytes. Functional ESC lines were successfully derived from MST blastocysts with normal euploid karyotypes and minimal mtDNA carryover (lower detection limit of 3%). Moreover, transfer of MST embryos into foster females resulted in the birth of three healthy infants with undetectable levels of mtDNA carryover in all tissues tested (Tachibana et al., 2009 (Tachibana et al., , 2010 (Table II) . The same technique has since been performed between mouse oocytes with different mtDNA genotypes, revealing a blastocyst formation rate of~90% and an average mtDNA carryover within reconstituted ST oocytes of <1% (Table II) . These animal studies confirm that MST is technically feasible, with reconstituted oocytes capable of normal fertilization and development to the blastocyst stage at a similar rate as unmanipulated controls. Furthermore, MST blastocysts can produce healthy offspring with minimal levels of karyoplast-derived mtDNA, confirming the potential of this technique to prevent transmission of mtDNA disease.
The first study to perform MST in human MII oocytes was published by Tachibana et al. (2013) , which confirmed the feasibility of the technique but also reported a significant proportion of human MST zygotes that displayed abnormal fertilization after ICSI. This higher rate of abnormal fertilization in human MST zygotes when compared to controls (52% vs 13%, respectively) was not observed in non-human primate MST zygotes and could be due to either premature oocyte activation caused by the procedure or spindle damage during enucleation and transfer (Tachibana et al., 2013) . The blastocyst rate in MST oocytes that showed normal fertilization, however, was comparable to controls (62% vs 76%, respectively), whilst the level of karyoplast-derived mtDNA in reconstituted MST embryos was low (0.5% ± 0.4%) and remained low during continued culture of hESC lines derived from MST blastocysts (0.6% ± 0.9%) (Table II) . Another study published around the same time performed MST in human MII oocytes, followed by parthenogenetic activation of reconstituted oocytes, and demonstrated that premature activation of oocytes could be avoided by partial depolymerization of the spindlechromosome complex by reduced temperature or cryopreservation of oocytes before performing MST. In addition, the study confirmed low levels of mtDNA carryover in reconstructed MST embryos, which decreased to undetectable levels during continued culture of hESC lines derived from MST blastocysts (Paull et al., 2013) (Table II) . Similar observations were made in recent studies by Yamada et al. (2016) and Kang et al. (2016) , both reporting consistently low or undetectable levels of karyoplast-derived mtDNA in most hESC lines derived from MST blastocysts. There were exceptions, however, with a limited number of hESC lines revealing an increase in karyoplast-derived mtDNA during culture. In some hESC lines, this was a transient increase followed by a reduction in the level of mtDNA carryover (Yamada et al., 2016) (Table II) , whilst in others, a complete reversion to the karyoplast-derived mtDNA genotype was reported (Table II) . Although this implies that even low levels of mtDNA carryover following NT could increase to levels above the threshold for mitochondrial disease, the results must be interpreted with some caution given that segregation of mtDNA in hESCs could be very different from the situation in vivo. Moreover, most reports on mtDNA segregation in hESCs have used stem cells containing heteroplasmic mtDNA that does not contain a pathogenic mtDNA mutation, which could segregate differently.
In addition, the study by Kang et al. (2016) was the first to perform MST using human MII oocytes from women carrying a pathogenic mtDNA mutation , providing the first evidence to confirm the potential of MST to reduce transmission of an mtDNA mutation to low levels (<1%) in MST blastocysts. Derivation of hESC lines from a limited number of these MST blastocysts revealed inconsistent effects on the level of karyoplast-derived mtDNA despite the presence of the mtDNA mutation, with one hESC line showing an increase in mtDNA carryover and two maintaining levels of <1% (Table II) .
There is currently one report of the clinical application of MST using human MII oocytes to prevent transmission of mtDNA disease resulting in live offspring . The procedure, which was performed by Zhang et al. (2017) in Mexico due to lack of approval in the US, resulted in the first live birth of an apparently healthy baby. The case involved a 36-year-old woman who experienced four miscarriages and two children who died due to high levels of a maternallyinherited mtDNA mutation (>95%) known to cause Leigh syndrome (m.8993T>G) . Following MST, the average level of mtDNA mutation load within the MST blastocyst selected for embryo transfer was 5.73%, whilst the average level within multiple tissues collected after birth was 1.60 ± 0.92% (range: 0-9.23%) (Zhang (Table II) . This study suggests that MST can effectively reduce transmission of a pathogenic mtDNA mutation and that MST blastocysts can give rise to a viable pregnancy and live birth. It is noteworthy, however, that the level of mtDNA carryover determined in the MST blastocyst transferred to the uterus was higher than previously reported in other studies that have investigated the potential of MST to prevent transmission of mtDNA disease. Furthermore, although the reported levels of mtDNA carryover in the neonatal tissues were low, it is still not known whether the mtDNA mutation could accumulate in various tissues or reverse to the karyoplast-derived mtDNA genotype over time. This highlights the importance of longterm follow-up of any children born following NT, as the information is vital for confirming the safety of this still experimental treatment.
Polar body transfer
Polar bodies (PBs) are small structures extruded from oocytes and zygotes during the first and second meiotic division. body (PB1) is diploid whilst the second polar body (PB2) is haploid and both contain identical genetic material to the oocyte or zygote. PB1 transfer (PB1T) involves removal of PB1 from a MII oocyte, followed by transfer to an enucleated MII oocyte with the maternal spindle removed and fertilization of the reconstituted oocyte (Fig. 3A) . PB2 transfer (PB2T) involves removal of PB2 from a fertilized PNstage zygote and transfer to a recipient zygote with the female pronucleus removed (Fig. 3A) . Both techniques have been successfully performed in mouse oocytes (Wakayama et al., 1997; Wakayama and Yanagimachi, 1998) , demonstrating the ability of PBT to produce developmentally competent embryos and generate live offspring. More recently, PBT has also been performed in mice to investigate the potential of these techniques to prevent transmission of mtDNA disease (Wang et al., 2014) . The study confirmed the feasibility of PBT whilst comparing the technique to both MST and PNT in terms of mtDNA carryover. This revealed undetectable or very low levels (<2%) of mtDNA carryover following PBT, compared to higher levels after MST (~6%) and PNT (~24%) (Wang et al., 2014) . The data confirm that PBT reduces mtDNA carryover, which is not surprising given that PBs are small and contain very little cytoplasm (Steuerwald et al., 2000; Gigarel et al., 2011; Dalton and Carroll, 2013; Wang et al., 2014) (Fig. 3A) , but also suggest that PBT results in lower levels of karyoplast-derived mtDNA when compared to other NT techniques. The mtDNA carryover reported for MST and PNT in this study, however, are higher than those reported in other studies and are not necessarily representative. In addition, after PB1T, the reformation of meiotic spindles was reportedly dependent on the residual meiotic activity of recipient enucleated MII oocyte (Ma et al., 2017) . Since the centrioles are derived from sperm (Sathananthan et al., 1991) , PB1T in unfertilized MII oocytes with cytoplasmic deficiency of PB1 might circumvent multipolar spindles or aneuploidy caused by abnormal centriole number (Ganem et al., 2009; Egli et al., 2011; Paull et al., 2013) . For PB2T, a potential problem is whether isolated PB2 contains adequate centrioles to support formation of mitotic spindles owing to its limited cytoplasm (Schatten and Sun, 2009 ). So far, few studies have investigated this issue. Nonetheless, in mice, PB2T zygotes have appeared to support normal preimplantation development and subsequent transfer of these PB2T embryos into pseudopregnant mice has resulted in healthy offspring (Wang et al., 2014) . This indicates that cytoplasmic deficiency of PB2 might not compromise the development of reconstructed embryos, at least in mice. There is currently only one report of PBT in human MII oocytes, which revealed that reconstituted PB1T oocytes were capable of normal fertilization (by ICSI) at a similar rate to unmanipulated controls. PB1T zygotes also had the potential for onward development but blastocyst formation was limited, with most (~58%) arresting before the blastocyst stage. The efficiency of hESC derivation from PB1T blastocysts was low, possibly due to poor blastocyst quality, but further analysis of these hESCs revealed no significant difference in gene expression when compared to controls (Ma et al., 2017) . This led the authors to conclude that PB1T could provide an additional technique to support the use of NT to overcome mitochondrial disease, although preclinical data is currently lacking and the limited embryonic development requires further investigation. There are currently no reports in the literature of PB2T in human oocytes, most likely due to the difficulty in distinguishing male and female PNs within human zygotes (Wang et al., 2014) , which makes the procedure technically challenging.
Germinal vesicle nuclear transfer
The germinal vesicle (GV) is the nucleus of an immature oocyte arrested in prophase I of the first meiosis. The method of GV transfer (GVT) involves removing the GV and transferring it to an enucleated oocyte that has had its own GV removed, followed by in-vitro maturation (completion of meiosis) and fertilization of the reconstituted oocyte (Fig. 3A) . In both animal and human studies, GVT has been used to investigate the mechanisms of oocyte meiosis and maturation (Fulka et al., 1998; Takeuchi et al., 1999 Takeuchi et al., , 2001 Zhang et al., 1999; Liu et al., 2000 Liu et al., , 2003 Li et al., 2001; Eichenlaub-Ritter et al., 2004; Chiang et al., 2012; Zhang, 2015; Zhang and Liu, 2015) , demonstrating that reconstituted GVT oocytes are capable of development to the blastocyst stage and can result in viable offspring, at least in mice (Liu et al., 2000 (Liu et al., , 2003 Cui et al., 2005; Takeuchi et al., 2005) . The potential for GVT to replace mutated mtDNA and prevent transmission of mtDNA disease has also been considered in mice. performed GVT between mouse oocytes and found that mtDNA carryover was undetectable in the resultant embryos. However, it was also reported that, although reconstituted GVT oocytes had the potential to complete maturation and undergo cleavage following parthenogenetic activation, all GVT zygotes arrested and did not reach the blastocyst stage , most likely due to inefficient culture media unable to adequately support the in-vitro maturation of oocytes. Further studies would be needed to improve the efficiency of this technique before it could be considered for clinical application, since in human oocytes, in-vitro maturation is still inferior to the use of in-vivo matured oocytes for IVF treatment (Chang et al., 2014) .
Clinical use of nuclear transfer to prevent mitochondrial DNA diseases
The first offspring in human after MST to overcome the transmission of a pathogenic mtDNA mutation was reported in the popular media in 2016 and has now been published . The resulting male infant was reported to carry low levels of karyoplast-derived mtDNA from the mother, suggesting that MST is an effective technique to reduce the risk of serious mtDNA disease . The same clinic is now planning a further 20 MST pregnancies in the first half of 2017 (https://www.newscientist.com/article/2 115 731-exclusivemexico-clinic-plans-20-three-parent-babies-in-2017/). In the UK, despite regulations being passed by the government to permit the clinical application of mitochondrial donation in March 2015 , the Human Fertilisation and Embryology Authority (HFEA) only recently approved 'cautious clinical use' of the technique in December 2016. This means that fertility clinics can now apply for a licence permitting the use of mitochondrial donation for prevention of serious mtDNA disease, with applications for each individual patient considered on a case-by-case basis. Similarly, a recent report published in the US concluded that clinical trials of NT should be permitted but with limitations (National Academies of Sciences, Engineering, and Medicine, 2016) , including the transfer of only male embryos, a condition that was rejected in the UK. At present, more scientific data are available to support the use of MST and PNT over the other NT techniques, but there is currently no indication of whether MST or PNT is preferable (http://www. hfea.gov.uk/docs/Fourth_scientific_review_mitochondria_2016.PDF). Until further evidence becomes available, which could include results from long-term follow-up studies of any children born after NT, it is likely that this decision will ultimately depend on the expertise of the fertility clinic performing the procedure, along with the views of the prospective parents. Some of the technical aspects of the different NT techniques are discussed below, with a particular focus on MST and PNT due to their recent clinical application, followed by a brief discussion of potential safety concerns.
Micromanipulation and technical aspects
The equipment necessary to perform NT, including the micromanipulation and optical systems, are routinely found in many IVF laboratories. This makes NT accessible to many clinics, but performing these techniques both effectively and safely requires the skill of a highlytrained embryologist. Important outcomes that must be taken into consideration include oocyte/zygote survival following NT, blastocyst development rate and the level of mtDNA carryover. These performance indicators could be highly variable between operators, emphasizing the need for training in NT procedures, but could also differ depending on the particular NT technique used.
MST is performed between unfertilized MII oocytes, which for some offers an advantage over PNT as it avoids the creation of zygotes for the purposes of treatment. The spindle karyoplast is smaller than the PN karyoplast, which could make the manipulation less invasive and with the potential for less karyoplast-derived mtDNA. The majority of studies in human embryos, however, show that both MST and PNT result in equivalent low levels of mtDNA carryover and so both have the same ability to reduce the risk of mtDNA disease in the offspring. Unlike PNT, the spindle is not surrounded by a nuclear membrane, meaning that the chromosomes aligned on the spindle could theoretically be lost or damaged during the NT procedure. Evidence from human oocytes suggest that this is possible, with chromosome scattering reported in oocytes from older women (Battaglia et al., 1996) and in response to temperature fluctuations in the surrounding environment (Almeida and Bolton, 1995) . This could lead to higher levels of aneuploidy after MST, which has not been described in most research studies of MST using human oocytes but was reported in the majority of MST blastocysts (80%) produced in the recent treatment cycle performed by Zhang et al. (2017) . MST using human oocytes can also result in higher levels (~50%) of abnormal fertilization following ICSI (Tachibana et al., 2013) , possibly due to spindle damage during the procedure, and could significantly reduce the efficiency of MST due to potentially fewer normal zygotes that could be selected for transfer to the uterus. Furthermore, the data available on the quality of MST blastocysts is limited, which makes it difficult to determine the likelihood of achieving a pregnancy following MST.
During final oocyte maturation, the nuclei-germinal vesicles break down (GVBD) and chromosomes condense. Chromosomes are then arranged at the MI stage within the MI spindle-chromosome complex, followed by the anaphase I to telophase I transition and extrusion of the first polar body. Oocytes become arrested at the MII stage containing the MII spindle-chromosome complex, alternatively known as the maternal spindle. When applying MST, meiotic spindles might be subjected to potential damage. Since the spindle-chromosome complex lacks a nuclear membrane in contrast to germinal vesicles, mechanical manipulation can disrupt this fragile structure (Kitajima et al., 2011) , resulting in possible loss of chromosomes from the spindle. This is likely the consequence of manipulation-induced tension leading to chromosome disattachment of meiotic spindles via reducing kinase phosphorylation (Liu et al., 2009; Paull et al., 2013) . In addition, when applying electrofusion to fuse the spindle with the recipient oocytes, premature oocyte activation caused by electrical currents can disrupt the transferred spindles, as shown by several published articles (Tachibana et al., 2009 (Tachibana et al., , 2010 Paull et al., 2013) . In a monkey model, immunocytochemistry analysis has shown that after MST, most of the resulting oocytes after electrofusion displayed signs of premature activation: progressing to the anaphase II stage with sister chromatids moving toward opposite poles; whereas following fusion by HVJ-E, the spindles of reconstructed oocytes were more stable at the MII stage with chromosomes correctly aligned at the equatorial plate (Tachibana et al., 2009) . Tachibana et al. (2013) showed that after fertilization, only half of the reconstructed MST oocytes showed normal fertilization, whereas 52% of MST zygotes displayed abnormal fertilization (1PN or ≥3PN) which could be indicative of a damaged spindle due to intensive micromanipulation (Tachibana et al., 2013) . Moreover, Paull et al. (2013) confirmed that low temperature during micromanipulation could also partially depolymerize isolated spindles (Paull et al., 2013) causing micro-or multinucleation after fertilization.
In contrast to MST, PNT offers the advantage of having the maternal and paternal genomes surrounded by a clearly defined nuclear membrane, which reduces the risk of chromosome abnormalities within the reconstituted zygote. In comparison to the spindle, the PNs are relatively large and migrate to the centre of the zygote after fertilization, which could make their removal more invasive. This is less likely to be an issue with early PNT, which has been associated with increased survival of reconstituted zygotes (Hyslop et al., 2016) . The removal of the PN immediately after they appear, at which point they are smaller and found closer to the periphery of the zygote, should help minimize the size of the PN karyoplast, although it is also possible to remove excess cytoplasm once the karyoplast has been removed from the zygote (Hyslop et al., 2016) . Some care must be taken when doing this, however, as the zygote must be able to form a normal bipolar spindle for mitosis which requires the presence of two centrioles. In humans, these centrioles are found in close proximity to the PN membrane (Sathananthan et al., 1991) , meaning that the karyoplast must retain enough cytoplasm to include the centrioles and any other spindle assembly components (Craven et al., 2011) . Current evidence suggests that this is not a problem, with no increase in the incidence of aneuploidy detected in PNT blastocysts when compared to both unmanipulated control blastocysts and a reference data set of age-matched IVF blastocysts (Hyslop et al., 2016) .
Briefly, PBT offers certain advantages over both MST and PNT, the main one being that polar bodies are effectively 'ready-made' karyoplasts that contain the nuclear DNA, and a small volume of cytoplasm, enclosed by a membrane. This should make their removal much less invasive and does not require the use of cytoskeletal inhibitors. Moreover, polar body biopsy is an IVF technique already performed in some clinics as an alternative to PGD (Montag et al., 2013; Cimadomo et al., 2016) . Another advantage is that given their small size and limited cytoplasm, polar bodies contain very few mitochondria when compared to the oocyte (Steuerwald et al., 2000) , meaning that the level of karyoplast-derived mtDNA within the reconstituted oocyte following PBT will be low. There are disadvantages, however, including the possible time constraints on PBT due to degeneration of polar bodies following their extrusion from the oocyte. Another current disadvantage is the low blastocyst development rate following PBT in human oocytes, which will need to be addressed if this technique is to be considered for clinical application.
Compatibility between mtDNA and nDNA
As mitochondrial function is under dual control of both the nuclear and mitochondrial genomes, an important concern with NT is whether the nuclear genome within the reconstituted oocyte/zygote is compatible with the mtDNA from the mitochondrial donor. Previous studies have proposed nuclear-mitochondrial incompatibility in a number of different animal models (Holmbeck et al., 2015; Ma et al., 2016 ) but this does not appear to be a consistent finding, with others reporting no harmful effects despite the presence of divergent mitochondrial genomes (Battersby and Shoubridge, 2001; Gregorova et al., 2008; Cannon et al., 2011) . It is important to note that these studies use highly inbred laboratory animals, which are very different to mostly outbred human populations, and so the relevance to NT continues to be debated (Reinhardt et al., 2013; Chinnery et al., 2014) . Furthermore, the health reports of macaques generated by MST, and now the birth of the first apparently healthy baby, have revealed no adverse effects from NT and suggest that nuclear-mitochondrial incompatibility is not an issue. Further reassurance is provided by the normal preimplantation development of NT embryos containing several different nuclear-mtDNA combinations, and the derivation and differentiation of embryonic stem cells from these blastocysts. Current evidence also suggests that mitochondrial function is not altered following NT in humans (Tachibana et al., 2013; Ma et al., 2015) . This was demonstrated in undifferentiated and differentiated ESCs derived from MST blastocysts, which revealed comparable mitochondrial respiratory chain enzyme activities and oxygen consumption rates irrespective of the nuclear-mtDNA combination Yamada et al., 2016) .
Potential increase in karyoplast-derived mtDNA
During the NT procedure, it is inevitable that a small volume of cytoplasm will be removed within the karyoplast and transferred with the nuclear genome. This cytoplasm will contain mitochondria and is likely to result in mtDNA carryover within the reconstituted oocyte/ zygote (Richardson et al., 2015) . This has been demonstrated in both human and animal studies, which revealed low levels of mtDNA heteroplasmy (below 2%) in the majority of reconstituted embryos regardless of the NT technique used (Tachibana et al., 2009; Craven et al., 2010; Hyslop et al., 2016; Kang et al., 2016; Yamada et al., 2016) . At this level, transmission of the pathogenic mtDNA mutation would be well below the threshold for disease expression and so the risk of mtDNA disease in the offspring would be minimal. However, a concern is that the level of heteroplasmic mtDNA could shift during embryonic development, as has been observed in a limited number of hESC lines derived from NT blastocysts (Fig. 3B ) or in some animal models (Neupane et al., 2015) . The study by Hyslop et al. (2016) observed a progressive increase in mtDNA carryover from~4% to 60% in one out of five ESC lines derived from PNT blastocysts (Hyslop et al., 2016) . Similarly, Yamada et al. (2016) reported an increase in mtDNA carryover from~1% to~53% in one out of eight stem cell lines derived from MST blastocysts, although this level subsequently decreased to 1% during further culture (Yamada et al., 2016) . Similar observations were made by Kang et al. (2016) after performing MST with human control oocytes and oocytes harbouring a pathogenic mtDNA mutation. Even though the mtDNA carryover within preimplantation embryos was <1%, three out of 18 ESC lines derived from MST blastocysts displayed an increase in mtDNA carryover to homoplasmic levels .
The reasons behind the increase in mtDNA carryover within hESC lines are still not understood. One hypothesis is that the karyoplastderived mtDNA has a replicative advantage due its proximity to the nucleus, which could increase availability of the nuclear-encoded factors required for mtDNA replication (Meirelles and Smith, 1998) . This is conceivable given that karyoplast-derived mtDNA is found within the perinuclear mitochondria that are transferred during NT, but it is unclear whether these mitochondria would remain perinuclear throughout preimplantation embryo development and subsequent ESC culture (Meirelles and Smith, 1998) . Another hypothesis is that the replicative advantage is due to sequence variants found within the karyoplast-derived mtDNA genotype, which are used to determine the mtDNA haplotype. Studies in animal models have revealed that the presence of divergent mtDNA haplotypes can result in proliferation of one mtDNA genotype over another (Burgstaller et al., 2014 (Burgstaller et al., , 2015 , leading to the recommendation that prospective mothers and mitochondrial donors are matched based on their mtDNA haplotype. The findings from human studies, however, are inconsistent and question the requirement for such haplotype matching. This was evident from the study by Kang et al. (2016) , whereby the mtDNA carryover in two separate hESC lines with the same combination of different mtDNA haplotypes revealed contrasting results, i.e. one hESC line reached homoplasmic levels of karyoplast-derived mtDNA whilst the other retained <1% (Table II) . Similar conflicting results were reported in hESC lines derived from SCNT blastocysts containing the same combination of mtDNA haplotypes (Yamada et al., 2016) (Table II) . Furthermore, the study by Hyslop et al. (2016) revealed that a shift in the level of karyoplast-derived mtDNA could occur even when the nuclear and mitochondrial donor belonged to the same haplogroup (Hyslop et al., 2016) (Table I) . However, the same haplogroup can contain many different mtDNA variants, with a difference of~20 mtDNA variants being not uncommon (Royrvik et al., 2016) . Therefore, the possibility remains that a particular variant could be responsible for the proliferative advantage of one particular mtDNA genotype over another. This was investigated in the study by Kang et al. (2016) and a polymorphism within the non-coding region of the mitochondrial genome (D-loop) identified as a potential variant that could be responsible . Although this is feasible given the involvement of the D-loop in mtDNA transcription and replication (Nicholls and Minczuk, 2014) , mtDNA variants within this region are not a consistent finding. It may also be important to consider the possibility that this observation is merely a feature of stem cell biology. Given that pluripotency exists only temporarily during in vivo embryo development, the relevance of ESCs as a model of post-implantation development is far from clear.
Safety considerations for NT
Despite the conflicting evidence around the potential for mtDNA haplotype mismatch, the most recent review on the safety and efficacy of mitochondrial donation in the UK recommended that haplotype matching is considered as a precautionary step when selecting suitable oocyte donors. Given that all oocyte donors will have their mtDNA fully sequenced to confirm the absence of any pathogenic mtDNA mutations, assigning haplotypes will be relatively straightforward. The problem may arise when trying to match these haplotypes to the women who carry the mtDNA mutation, as precise matching of every mtDNA variant could prove challenging, if not impossible, and could limit use of the technique unnecessarily. Further research is required to determine the relevance of the observations made in hESCs but should not delay the clinical application of NT to reduce the risk of mitochondrial disease. In the meantime, NT should be considered in combination with prenatal screening to identify any changes in the level of mtDNA carryover that could increase the risk of mtDNA disease (Hyslop et al., 2016) . This also highlights the importance of longterm monitoring of any children born following NT.
Another potential problem which should be taken into account is whether NT techniques could induce genomic imprinting changes in resultant embryos or offspring (Reik et al., 1993; Lorthongpanich et al., 2013) . Until now, there are still limited data in the literature addressing this issue. In mice, Wang et al. (2014) demonstrated that prior to PBT, no remarkable differences in patterns of epigenetics, DNA methylation and histone modifications between PB1/2 chromosomes and the corresponding oocyte/zygote exist. After the application of PBT, the offspring displayed normal development, which led them to conclude that 'this technique is unlikely to cause epigenetic and imprinting defects' (Wang et al., 2014) . Consistently, through analysis of DNA methylation and imprinted genes, other mouse model studies have not revealed significant epigenetic and imprinting abnormalities in tissues of GVT-derived offspring (Takeuchi et al., 2005; Cheng et al., 2009) . In humans, Paull et al. (2013) showed that no epigenetic/genetic alterations were present in embryos after the application of MST compared to unmanipulated controls (Paull et al., 2013) . To a more extended level, using genome-wide RNA sequencing, Hyslop et al. (2016) demonstrated that global gene expression in early PNT blastocysts did not differ from unmanipulated controls (Hyslop et al., 2016) . Furthermore, examination of ESCs derived from PB1T and control blastocysts revealed that patterns of DNA methylation and global gene expression in PB1T ESCs were similar to the controls (Ma et al., 2017) . Although these aforementioned studies did not reveal any severe adverse imprinting/epigenetic changes caused by the NT procedure, we recommend cautious clinical use of this technology and follow-up of the offspring after application of this NT technology.
Application of nuclear transfer and alternative technologies for infertility
Over the past decade, the number of ART procedures have increased substantially and conventional technologies, like IVF and ICSI, have been extended with the help of more advanced technologies, such as time lapse imaging, use of '-omic' technologies, assisted oocyte activation, advanced freezing methods and more (Heindryckx et al., 2005; NasrEsfahani et al., 2010; Ben-Meir et al., 2015; Szamatowicz, 2016) . Contrary to the overall perception, however, ART does not guarantee success, as between 38% and 49% of couples who start an in-vitro treatment will remain childless, even when they undergo up to six treatment cycles (Malizia et al., 2009; van Loendersloot et al., 2014) . However, these numbers seem rather pessimistic as more recently, De Vos et al. (2016) reported a cumulative live birth rate of >52% per IVF/ICSI cycle (De Vos et al., 2016) . Another recent study also revealed that cumulative live birth rate after three IVF cycles was 42.3% and following eight IVF cycles, this rate of live birth would be 82.4% (McLernon et al., 2016) . The chance for success is of course correlated with female age, as ART largely overcomes infertility in younger women but does not completely reverse the age-related decrease in fertility (van Loendersloot et al., 2014) . The role of mitochondria in infertility continues to be debated. It is known that with ageing, the number of different mitochondrial deletions and point mutations increase significantly (Cortopassi et al., 1992) , and it is estimated that up to 50% of human oocytes contain mutated or deleted mtDNA (Chan et al., 2005; Jacobs et al., 2007) . Also in males, multiple deletions of mitochondrial DNA have been reported in human sperm, especially in ageing men or those with poor quality sperm (Kao et al., 1998) . Thus, it is reasonable that damaged mitochondria may play a vital role in some unresolvable cases of infertility which could be overcome by the application of NT technologies. However this is contradicted by the fact that live birth rates among women with mtDNA disease are comparable to the general population, implying normal fertility despite the presence of a pathogenic mtDNA mutation (Gorman et al., 2015a) .
Female infertility and role of mitochondria
There is considerable variation in the number of mtDNA molecules present in human oocytes, ranging from 20 000 up to 600 000 copies, which could be indicative of the wide-ranging quality in human oocytes (Wang and Moley, 2010) . The mtDNA copy number in oocytes from older women, or women with diminished ovarian reserve, is significantly lower than the number in younger woman or those with a normal ovarian reserve (Murakoshi et al., 2013; May-Panloup et al., 2016) . In older women, this coincides with a lower mtDNA content in earlycleavage stage embryos, but paradoxically, the opposite was observed at the blastocyst stage, with a higher mtDNA content associated with increased aneuploidy and failed implantation (Fragouli et al., 2015) . An explanation for this is that mitochondrial proliferation may occur as a compensatory mechanism for mitochondrial dysfunction when the embryo is stressed (Schon and DiMauro, 2003) . Importantly, it has been suggested that a threshold for mtDNA copy number is required to support fertilization and subsequent embryonic development efficiently (Schatten et al., 2014) .
There are increasing energy demands when an oocyte matures, requiring a shift from glycolysis to oxidative phosphorylation, reaching a peak at the time of ovulation (Cotterill et al., 2013) . Key processes during oocyte maturation, such as formation of the spindle and correct metaphase alignment of the chromosomes, depend on an adequate supply of mitochondrial-derived ATP (Schatten et al., 2014) . Energy for the subsequent events of fertilization and embryonic development up to the blastocyst stage is provided solely by the pool of mitochondria present in the mature oocyte, since no mitochondrial replication is thought to occur until the hatched blastocyst stage (St John et al., 2010) . It stands to reason, therefore, that any deficiencies in the mitochondria may hamper the crucial processes of maturation, fertilization and embryonic development, as was observed following disruption of OXPHOS in mouse oocytes leading to meiotic spindle abnormalities and subsequent decreased embryonic development (Zhang et al., 2006) . There is substantial proof that meiotic and embryonic aneuploidies are related to both female age and mitochondrial activity (Schatten et al., 2014) , and so oocyte competence, including cytoplasmic quality and particularly the mitochondria, may be affected by ageing (Meldrum et al., 2016) . These aneuploidies, present in oocytes and resulting embryos are widely considered an important cause of female infertility, resulting in spontaneous abortion and repeated implantation failure, especially in advanced maternal age (May-Panloup et al., 2016) . For more information on infertility and the role of mitochondria, reviews are available (Benkhalifa et al., 2014; Schatten et al., 2014; Otten and Smeets, 2015; May-Panloup et al., 2016; Demain et al., 2017) .
Ooplasmic transfer
The method of ooplasmic transfer (OT) involves removing cytoplasm, which will contain mitochondria along with many other cellular components, from a donor MII oocyte and transferring it to a recipient oocyte. Early animal studies demonstrated the feasibility of this technique, which was reported to increase intracellular ATP concentrations (Van Blerkom et al., 1998) and/or prevent apoptosis (Perez et al., 2000) following cytoplasmic injection into mouse oocytes. In cow, oocytes artificially depleted of mtDNA could be rescued by OT and give rise to normal offspring (Ferreira et al., 2007; Chiaratti et al., 2011) . To overcome female infertility due to possible poor oocyte cytoplasmic quality, supplementation of human oocytes with donor cytoplasm from younger oocytes was performed in the 1990s by several fertility clinics in the US. This involved the injection of a limited amount (1-5%) of cytoplasm from healthy MII oocytes into patient's oocytes (Cohen et al., 1997 (Cohen et al., , 1998 Huang et al., 1999; Spikings et al., 2006) . This experimental treatment led to almost 50 pregnancies (Cohen et al., 1997; Huang et al., 1999; Lanzendorf et al., 1999; Barritt et al., 2001a Barritt et al., , 2001b Dale et al., 2001) but was considered controversial due to a lack of prior animal studies to confirm both the benefits and safety of this technology. Moreover, certain chromosomal anomalies (Turner's syndrome, XO karyotype) as well as infant defects (borderline pervasive developmental disorder) were reported in the children born following OT (Barritt et al., 2001b; Brown et al., 2006) . Given the limited sample size, it is not possible to prove that these anomalies were caused by the OT procedure itself but due to these adverse outcomes, the US Food and Drug Administration suspended the use of OT in human oocytes in 2002. More recently, Chen et al. (2016) conducted a follow-up study on 13 children born following OT (13-18 year-old) and reported that general health and cognitive ability seemed normal, with minor skin problems, minor vision problems, mild asthma and chronic migraine headaches described (Chen et al., 2016) . OT is not a suitable approach to prevent transmission of a pathogenic mtDNA mutation as very large amounts of donor cytoplasm would need to be transferred into the patient's oocyte to adequately dilute the mutant mtDNA and reduce the risk of mtDNA disease, which is practically not possible in humans (Thorburn and Dahl, 2001; Tachibana et al., 2009) .
Mitochondrial replacement
The transfer of mitochondria harvested from somatic cells, or more recently stem cells, has been suggested as possible treatment strategy to overcome certain forms of infertility. The benefit of mitochondrial supplementation originating from follicular cells has been shown in cattle (Hua et al., 2007) , and in humans (Tzeng et al., 2004) . However, atresia of oocytes is known to be induced by apoptotic signals emitted by follicular cells (Hussein et al., 2005) , posing a major risk of oocyte degeneration. Moreover, mitochondria harvested from the same somatic cells as the recipient oocyte will most likely also contain the disadvantages related to aged mitochondria. Therefore, high quality autologous mitochondria would be better suited for energy augmentation of oocytes through mitochondrial replacement. The possibility of using mitochondria harvested from oocyte precursor cells present in the ovary (Johnson et al., 2004; White et al., 2012) was suggested. There is some controversy around this, however, as some studies have failed to identify mitotically active female germline progenitors in postnatal mouse ovaries (Zhang et al., 2012) . Although their role is still obscure, these precursor cells would not have experienced an extended period of meiotic arrest, making it possible that they could contain fewer mtDNA mutations and deletions (Yabuuchi et al., 2012) . Still, experimental proof of the benefit of this mitochondrial replacement from oocyte precursor cells into oocytes is currently lacking, both in animal models and especially for infertility indications. For women with multiple IVF failures, this technology depicted as 'Autologous Germline Mitochondrial Energy Transfer (AUGMENT SM )', involves the injection of 1-2pL of harvested mitochondria into the patient's MII oocytes along with the sperm and has been applied in several infertile couples (Fakih et al., 2015; Oktay et al., 2015) . Although claiming the benefits of this treatment, the small number of patients (Oktay et al., 2015) or biased study design (Fakih et al., 2015) make it difficult to validate this technology. As with OT, the large number of healthy mitochondria required to adequately dilute the mutant mtDNA prevents this AUGMENT technology being used to reduce the risk of mitochondrial diseases, which requires mitochondrial transfer in a heterologous manner (mitochondria harvested from another individual).
Nuclear transfer for infertility
To date, several nuclear transfer techniques discussed in the section 'The use of nuclear transfer technologies in animal and human models' have been proposed to overcome some forms of female infertility. Briefly, using these technologies, the nucleus from an oocyte collected from an 'infertile woman' is transferred to a donor oocyte that has had its own nucleus removed. Based on an abstract published back in 2003, Zhang et al. (2016b) recently reported the details of their clinical application of PNT for an infertile couple who had experienced two failed IVF cycles with repeated embryo arrest at the 2-cell stage. As many as five reconstructed zygotes that cleaved to the 4-cell stage on Day 2 were transferred, resulting in a triplet pregnancy. After foetal reduction to a twin pregnancy, one non-viable foetus was delivered due to premature rupture of the membranes at 24 weeks of gestation, while the other non-viable foetus delivered after intrauterine foetal demise due to cord prolapse at 29 weeks (Zhang et al., 2016b) . A normal karyotype was detected in the foetal material, and fingerprinting confirmed the nuclear origin from the patient and mtDNA from the donor, with no patient mtDNA detected. Although there is some circumstantial evidence that the oocyte cytoplasm is one of the most crucial factors for success in ART, it is recommended that this NT technology should not be currently used for infertility treatment. This is mainly because the evidence for which category or infertility indication this technology could benefit is currently lacking. The existence of suitable infertile animal models to explore the efficacy and safety of these NT technologies would be an advantage.
Conclusions
While NT techniques have been shown to effectively reduce the transmission of heteroplasmic mtDNA variants in animal and human studies, in most cases, there is still some transmission of mtDNA derived from the karyplast. One way to avoid the potential increase in levels of karyoplast-derived mtDNA and guarantee prevention of mtDNA disease would be to completely eliminate all mtDNA within the karyoplast. This could be achieved by induction of mitophagy (Diot et al., 2016) or through the use of nucleases targeted to specific mtDNA sequences, including mitochondrially-targeted zinc finger nucleases (mtZFNs) or mitochondrially-targeted transcription activator-like effector nucleases (mitoTALENs) (http://www.hfea.gov.uk/docs/Fourth_scientific_review_ mitochondria_2016.PDF). Although this would require validation, it could remove the potential risk of increasing mutant mtDNA within the offspring. This technology of genomic editing has also been proposed as another potential strategy for circumventing mitochondrial disease (Alexeyev et al., 2008; Hashimoto et al., 2015; Wang et al., 2015; Fogleman et al., 2016; Gammage et al., 2016; Patananan et al., 2016; Vassena et al., 2016) . In a proof of concept study, the group of Gammage et al. (2014) have succeeded in creating mtZFNs, which could target the mtDNA sequences of interest. In this way, the mtZFNs were able to specifically degrade mtDNA carrying pathogenic point mutations such as m.8993T>G or eliminate common deletions such as the 4977-bp deletion (Gammage et al., 2014) . Furthermore, Reddy et al. (2015) have demonstrated the efficacy of mitoTALENs in the mammalian germline, by decreasing the level of either m.14459G>A LHON or m.9176T>C mtDNA mutations (Reddy et al., 2015) . Also the popular CRISPR/Cas9 genomic editing tool has been applied to target the mitochondrial copies in human kidney cell lines (Jo et al., 2015) .
In conclusion, increasing evidence supports the use of NT to prevent the transmission of human mtDNA disease, yet robust, longterm evaluation is highly warranted. Moreover, prenatal screening would still be strongly advocated in combination with the NT technology. Scientific evidence to support the use of NT or alternative reproductive techniques aiming at mitochondrial replacement for infertility indications is currently lacking.
